Neglected tropical diseases (NTDs) are the most common affliction of the world’s poorest people. Thriving in communities that lack access to health services, adequate sanitation and clean water, NTDs blind, disable and disfigure, trapping families in a cycle of poverty and disease.

An estimated two billion people lack the medicines they need. The 2016 Access to Medicines Index analyzes pharmaceutical companies’ efforts to improve access to medicines, vaccines and diagnostics for low- and middle-income countries.

Sabin Vaccine Institute President Dr. Peter Hotez gave the keynote address on NTDs at the Pontifical Council for Health Care Workers’ XXXI International Conference, focused on NTDs and rare diseases.

Last year, the leaders of some of the wealthiest nations pledged help control and eliminate the most common neglected tropical diseases (NTDs) by 2020.

by Peter Hotez, M.D., Ph.D. Hotez is Dean of the National School of Tropical Medicine at Baylor College of Medicine where he is also the Texas Children’s Hospital Endowed Chair in Tropical Pediatrics and the University Professor of Biology at Baylor University.

Last week, researchers, academics, doctors and advocates from all over the world gathered in Mexico City, Mexico at the 13th International Congress of Parasitology (ICOPA). Sabin Vaccine Institute (Sabin) President Dr.

More than half of the world’s population is at risk of contracting diseases carried by small organisms like mosquitoes, snails and sand flies.

Today, Sabin President Dr. Peter Hotez contributed a story to Foreign Policy about how little known neglected tropical diseases (NTDs) are wreaking havoc in some of the world's wealthiest nations. This and other stories in today's News Roundup.
Earlier this week 13 pharmaceutical companies*, together with several government and nongovernmental organizations**, pledged to find solutions to eliminate or control 10 neglected tropical diseases (NTDs) by the year 2020. At an event in London, pharmaceutical companies committed to invest in research and development (R&D) to find new treatments for NTDs along with increasing donations of existing drugs.